Ligand Pharm (LGND) Stock Price, Quote & News

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 550 7500

Website: www.ligand.com

Address:

555 Heritage Drive, Suite 200, Jupiter, United States

JamesTaulman Jul. 9 at 2:35 AM

$LGND – WED: The 10 DMA Has Now Caught Price to Act as Guiding Support Again 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-8-lgnd-the-10-dma-has-now-caught-price-to-act-as-guiding-support-again/

0 · Reply

IN0V8 Jul. 8 at 3:13 PM

$LGND Stifel raises target price to $332 from $255

0 · Reply

JamesTaulman Jul. 8 at 3:18 AM

$LGND – TUE: Remains Near New Highs 9:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-7-7-lgnd-remains-near-new-highs/

0 · Reply

JamesTaulman Jul. 7 at 3:11 AM

$LGND – MON: Holding Up a New Highs as the 10 DMA Races to Catch Up 7:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-7-6-lgnd-holding-up-a-new-highs-as-the-10-dma-races-to-catch-up/

0 · Reply

Mandalo Jul. 6 at 5:10 PM

$LGND At RANI the path to become a LeGeND has started today 🤑👍

0 · Reply

Mandalo Jul. 5 at 6:29 AM

$RANI is a pure "diamond in the rough" reminiscent of a young $LGND. Its payload-agnostic RaniPill platform shares the same capital-efficient, high-leverage royalty blueprint: Platform Scalability: Like Ligand’s Captisol, Rani’s mechanical capsule can oralize hundreds of multi-billion dollar biologics (from TNF-inhibitors to GLP-1s) without changing the core tech. Massive Operating Leverage: By utilizing strategic partnerships (like Chugai and ProGen) to fund late-stage clinical trials and commercialization, Rani protects its balance sheet while retaining massive royalty upside. While $LGND is a proven, profitable giant, micro-cap $RANI sits at an explosive inflection point. If larger trials validate its mechanical delivery system, the royalty-model leverage will be exponential. High risk, but asymmetric reward.

1 · Reply

MikeyMcDermott Jul. 4 at 12:23 AM

Paul Hastings, eh? $SPRO $LGND ? $XOMA ? $KLRA $GSK ?

0 · Reply

JamesTaulman Jul. 3 at 2:24 AM

$LGND – THU: Some Consolidation Action Here Above $300 Would Be Ideal 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-7-2-cinf-continues-to-get-extended-from-the-10-dma-at-180-74/

0 · Reply

JamesTaulman Jul. 2 at 3:25 AM

$LGND – WED: Finally Prints a Down Day – Volume Still Elevated 10:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-1-lgnd-finally-prints-a-down-day-volume-still-elevated/

0 · Reply

BioRich Jul. 1 at 4:46 PM

$TEM Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) $CGON 42) TEM 43) $IVA 44) $PSN 45) $LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

Market Cap	6.40B
Revenue (ttm)	268.09M
Net Income (ttm)	124.45M
EPS (ttm)	N/A
PE Ratio	43.48
Forward PE	75.39
Profit Margin	46.42%
Debt to Equity Ratio	0.00

Volume	117,325
Avg Vol	354,510
Day's Range	N/A - N/A
Shares Out	20.04M
Stochastic %K	71%
Beta	1.10
Analysts	Strong Sell
Price Target	$271.00